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Abstract
Background: Radiation therapy is an essential modality in the treatment of breast cancer. Addition of radiotherapy
to surgery has significantly increased local control and survival rates of the disease. However, radiotherapy is also
associated with side effects, such as tissue fibrosis or enhanced vascular morbidity. Modern radiotherapy strategies,
such as intensity modulated radiotherapy (IMRT), can shorten the overall treatment time by integration of the
additional tumor bed boost significantly. To what extent this might be possible without impairing treatment
outcome and cosmetic results remains to be clarified.
Methods/Design: The IMRT-MC2 study is a prospective, two armed, multicenter, randomized phase-III-trial
comparing intensity modulated radiotherapy with integrated boost to conventional radiotherapy with consecutive
boost in patients with breast cancer after breast conserving surgery. 502 patients will be recruited and randomized
into two arms: patients in arm A will receive IMRT in 28 fractions delivering 50.4 Gy to the breast and 64.4 Gy to
the tumor bed by integrated boost, while patients in arm B will receive conventional radiotherapy of the breast in
28 fractions to a dose of 50.4 Gy and consecutive boost in 8 fractions to a total dose of 66.4 Gy.
Discussion: Primary objectives of the study are the evaluation of the cosmetic results 6 weeks and 2 years post
treatment and the 2- and 5-year local recurrence rates for the two different radiotherapy strategies. Secondary
objectives are long term overall survival, disease free survival and quality of life.
Trial Registration: ClinicalTrials.gov Protocol ID: NCT01322854.
Background
Breast cancer is the most common cancer entity in
women in developed countries, representing a major
health care problem. The disease is diagnosed in about
1.2 million patients and accounts for about 500,000
deaths yearly worldwide [1]. Treatment is based on
stage, histology and biomarkers and is commonly multi-
modal. The development of diagnostic strategies has led
through the years to an earlier diagnosis of breast can-
cer, which resulted in the evolution from entirely surgi-
cal treatment into more conservative approaches,
replacing mastectomy by breast-conserving surgery
followed by radiation therapy in early-stage disease [2].
Adjuvant whole-breast external beam radiotherapy has
been shown to result in a significant increase of local
control, as well as a significant reduction in the risk of
death [3], making the outcome of breast-conserving sur-
gery comparable to mastectomy. Furthermore, additional
boost-irradiation to the tumor bed is found to further
improve local tumor control. In particular, 10-year
cumulative incidence of local relapse in the randomized
prospective trial comparing whole-breast irradiation ver-
sus whole-breast irradiation and subsequent boost was
10.2% versus 6.2% [4]. Further analyses have revealed an
increased benefit for patients younger than 50 years and
patients with high grade invasive ductal carcinoma [5].
The most common adjuvant radiotherapy strategy
after breast-conserving surgery consists of irradiation of
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during a 5-6 week period, with doses of 1.8-2.0 Gy per
fraction to a total dose of approximately 50 Gy. There-
after, boost irradiation is carried out using electrons
and/or photons up to a total dose of 66 Gy, resulting in
total treatment duration of 7-8 weeks.
Dose escalation by a sequential boost regimen results
in a longer treatment duration. Furthermore, various
studies have demonstrated that higher radiation dose is
associated with a limited but statistically significant wor-
sening of the cosmetic result, mainly due to breast fibro-
sis. In particular, the risk of moderate or severe fibrosis
at 10 years after breast conserving surgery followed by
whole breast irradiation with or without boost-irradia-
tion of 16 Gy was significantly increased for the group
of patients that had received a boost (12.6% versus
26.9%) [6].
Another important aspect in radiation therapy of
breast cancer is the fact that although radiotherapy is
associated with reduced disease-specific mortality, an
increase of cardiovascular mortality after radiation treat-
ment has been shown, with a trend towards higher risk
for women with left-sided disease [7]. Radiation asso-
ciated cardiac disease can manifest either as acute
injury, i.e. pericarditis, or as late injury, such as conges-
tive heart failure, ischemia, coronary artery disease or
myocardial infarction months to years post radiation
therapy [8]. Volume-dependent perfusion defects after
irradiation of left-sided breast cancer using tangential
photon beams to a dose of 50 Gy and electron boost of
16-18 Gy has been revealed for up to 40% of patients
within 2 years after treatment [9]. The risk for heart dis-
ease post-irradiation is higher for younger patients and
is further enhanced by the established use of anthracy-
clines in multimodal treatment regimes [10].
The limitations in radiation therapy of breast cancer
reveal the necessity for the use of advanced radiation
therapy strategies that allow a more accurate delivery of
radiation dose to the target volume sparing the sur-
rounding healthy tissues. A promising technology to
achieve this goal is intensity modulated radiotherapy
(IMRT). IMRT is an advanced technique using compu-
ter-assisted inverse planning and administering radiation
via multiple individual segments. Varying intensities
across each beam allow improvement of dose homoge-
neity. Delivery of irradiation to irregularly shaped targets
is optimized with IMRT, while the technology offers the
ability to produce concavities in the treatment volume
and therefore increase conformality. Trials in breast can-
cer patients have demonstrated better dose uniformity
throughout the breast for intensity modulated radiother-
apy with a median of 0.1% of the treatment volume
receiving ≥110% of the prescribed dose versus 10% with
conventional wedges [11]. Helical tomotherapy is an
advanced technology for intensity modulated radiother-
apy using an image-guided, dynamic, therapy delivery
system, which offers the potential for pretreatment
megavoltage CT imaging. Pretreatment imaging for
patient positioning verification is of high importance,
since it allows corrections for inter-fraction positioning
errors, which is a prerequisite for accurate delivery of
complex IMRT treatment plans [12]. Studies in breast
cancer patients comparing tomotherapy with 3D-plan-
ning demonstrated a minimal dose increase but
improved dose homogeneity and conformity to the plan-
ning target volume [13].
A major advantage of IMRT is also the fact that, in con-
trast to conventional techniques, it provides the possibility
to integrate the boost concept in the daily radiation ses-
sions by increasing the dose per fraction within the boost
volume [14]. Hence, overall treatment duration can be
shortened by more than one week compared to conven-
tional radiation treatment in patients, who are likely to
benefit from an additional boost to the tumor bed.
Thus, aim of this prospective, two-armed, multicenter,
randomized trial is to compare the results of intensity-
modulated radiotherapy versus conventional radiother-
apy for adjuvant treatment of breast cancer. Rationale of
the project is the reduction of treatment duration in
view of at least consistent radiation toxicity, local con-
trol, disease-free survival and overall survival, with
emphasis given to the cosmetic results and local control
after adjuvant treatment.
Methods/Design
Trial organization
The trial has been designed by the study initiators at the
Department of Radiation Oncology and the Department
of Gynecology of the University of Heidelberg. The trial
is carried out at the University of Heidelberg, Depart-
ment of Radiation Oncology and Department of Radia-
tion Oncology, University Medical Center Mannheim.
The University of Heidelberg is responsible for trial
management and coordination, as well as quality assur-
ance including reporting, monitoring and database
management.
Study design
IMRT-MC2 is a prospective, two-armed, multicenter,
randomized, phase III trial. The trial workflow and
treatment arms are depicted in Figure 1.
Patients fulfilling the inclusion criteria will be rando-
mized into two arms:
Arm A- Experimental Arm
IMRT of the whole residual breast to a total dose of
50.4 Gy and 1.8 Gy per fraction with 2.3 Gy per fraction
within integrated boost to the tumor bed to a total dose
of 64.4 Gy in 28 fractions.
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Conventional radiotherapy of the whole residual breast to
a total dose of 50.4 Gy and 1.8 Gy per fraction in 28 frac-
tions, followed by consecutive boost to a total dose of
66.4 Gy and 2 Gy dose per fraction in 8 fractions. A total
of 36 fractions is given to patients included in arm B.
Study objectives
Primary objectives of the study are cosmetic result and
local control rate after radiotherapy. The cosmetic result
will be evaluated at 6 weeks and 2 years post radiother-
apy. Local control will be evaluated at 2 and 5 years
post treatment.
Secondary objectives of the trial are quality of life at 6
w e e k sa n d2y e a r sa f t e rr a d i o t h e r a p y ,a sw e l la so v e r a l l
survival and disease free survival at 6 weeks, 2, 5, 10
and 15 years post radiation treatment.
Investigators
Patient treatment will be performed by radiation oncolo-
gists at the Department of Radiation Oncology at the Uni-
versity of Heidelberg and the Department of Radiation
Oncology at the University Medical Center Mannheim.
Data Handling, Storage and Archiving
All findings including clinical and laboratory data will be
documented by the investigator or an authorized mem-
ber of the study team in the subject’s medical record
and eCRF (electronic Case Report Form). The investiga-
tor is responsible for ensuring that all sections of the
eCRF are completed correctly and that entries can be
verified against source data. In some cases, the eCRF, or
part of the eCRF, may also serve as source documents:
Karnofsky Performance Status, Documentation of Cos-
metic Result and Clinical Examination.
Data will be collected and entered in a study specific
database by the Study Center of the Department of
Radiation Oncology at the University of Heidelberg and
the Study Center of the Department of Radiation Oncol-
ogy at the University Medical Center Mannheim.
All missing data or inconsistencies will be reported
back to the investigators and clarified by the responsible
investigator. If no further corrections are to be made in
the database it will be declared closed and used for sta-
tistical analysis.
The data will be stored and archived according to §13
of the German GCP-Regulation and §28c of the German
X-Ray Regulation (RöV) and §87 of the German Radia-
tion Protection Regulation (StrlSchV) for at least 30
years after the trial termination.
Data management for this study will be coordinated
by the Coordination Centre for Clinical Trials (KKS)
Heidelberg.
Ethics, informed consent and safety
The final protocol was approved by the University of
Heidelberg ethics committee (S-041/2009) and the Fed-
eral Office of Radiation Protection (BfS) (Z5-22461/2-
2009-018). The trial is sponsored by the German Aero-
space Center (DLR)/Federal Ministry of Education and
Research (BMBF) of Germany (01ZP0504). This study
complies with the Helsinki Declaration and its recent
German version, the Medical Association code of con-
duct, the principles of Good Clinical Practice (GCP) and
the Federal Data Protection Act. The trial will be carried
out in keeping with local legal and regulatory require-
ments. The medical secrecy and the Federal Data Pro-
tection Act will be followed. The ClinicalTrials.gov
Protocol ID is NCT01322854.
Patient selection
Inclusion criteria
Patients meeting the following criteria will be considered
for admission to the trial:
￿ All patients aged >18 years and <70 years after
breast conserving surgery.
￿ Patients aged ≥70 years with following risk factors:
Figure 1 Trial flow-chart.
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Page 3 of 8○ Tumor stage ≥T2
○ Multifocal disease
○ Lymphangiosis
○ Extended intraductal component
○ Resection margin ≤3m m
Exclusion criteria
Patients presenting with one of the following criteria
will not be included in the trial:
￿ Refusal of the patients to be included in the study
￿ Karnofsky Performance Score ≤70%
￿ Metastatic disease (M1)
￿ Other malignancies
￿ Previous radiotherapy of the breast
￿ Pregnancy
Study plan
502 patients (251 patients in each arm) with breast can-
cer and previous breast conserving surgery are included
in the study according to the criteria above. Eligible
patients are informed about participation in the trial
with possible benefits and risks, and written informed
consent is obtained. Patients are randomized into the
two treatment arms after baseline photo-documentation
and evaluation of the postoperative cosmetic result
through an expert panel and the patient, as well as eva-
luation of life quality using an EORTC questionnaire.
Treatment planning and radiation therapy
Arm A
A f t e rr e l i a b l ep a t i e n tp o s i t i o n i n g ,at h o r a c i cC Ts c a n
with a slice distance of 3 mm is carried out. Based on
the CT data set, radiation treatment planning is per-
formed as inverse planning using the planning tool Kon-
Rad
® (Siemens OCS, Erlangen, Germany). Multiple
fields arranged in a star-shape around the ipsilateral
hemithorax are chosen. Intensity modulation is opti-
mized according to the specified dose directions apply-
ing an inverse treatment planning technique. 6 MV-
photons are used for irradiation. IMRT can be applied
either in step-and-shoot technique at a linear accelerator
or at a dedicated tomotherapy unit. During treatment,
regular image guidance via MV-CT is carried out for
positioning control.
The clinical target volume (CTV) for the residual
breast tissue and - in certain cases - the locoregional
lymphatics, will be defined according to the S3 guide-
lines of the German Cancer Society [15]. The CTV for
Arm A includes the residual breast up to 5 mm under
the skin surface. The primary target volume (PTV)
includes the CTV with a margin of 10 mm in all
directions when optimization via virtual bolus concept is
possible. In Arm A/Tomotherapy or Arm A/IMRT with-
out virtual bolus concept the PTV will not be extended
over the skin surface. The GTV includes the tumor bed,
as defined by preoperative mammography.
IMRT treatment is performed in 28 fractions with 1.8
Gy per fraction to a total dose of 50.4 Gy and integrated
boost with 2.3 Gy per fraction to a total dose of 64.4 Gy.
This is equivalent to the dose of the conventional treat-
ment arm in consideration of the linear-quadratic model.
CTV will be covered by 45 Gy, GTV will be covered by
95% of the prescribed dose i.e. 60.8 Gy. With regard to
the organs at risk, less than 10% of the heart volume may
receive >30 Gy, while less than 20% of the ipsilateral lung
may receive more than 20 Gy. The mean dose to the con-
tralateral breast should be limited to less than 5 Gy.
In case dose to the target volume and dose limits to
t h eo r g a n sa tr i s kc a nn o tb em e ta tt h es a m et i m e ,
compliance with the threshold dose in the target volume
is paramount. However, dose limitations in contralateral
structures have to be met.
Treatment duration is 5
3/5 weeks with 5 fractions per
week.
Arm B
Patient positioning can be performed according to the
standards of the participating medical centers and will
be controlled weekly by conventional verification films.
For treatment in Arm B thoracic scans with a slice dis-
tance of 10 mm are allowed.
The clinical target volume (CTV) includes the residual
breast to the skin surface and in certain cases the locor-
egional lymphatics, according to the S3 guidelines of the
German Cancer Society [15]. The primary target volume
(PTV) includes the CTV with a medio-lateral and cra-
nio-caudal margin of 10 mm, as well as a ventral margin
of 20 mm. The GTV includes the tumor bed, as defined
by preoperative mammography.
Conventional radiation treatment of the residual
breast is performed in 28 fractions with 1.8 Gy per frac-
tion to a total dose of 50.4 Gy. Subsequently, a consecu-
tive boost to the tumor bed is carried out with 2 Gy per
fraction in 8 fractions to a total dose of 66.4 Gy.
Patients treated in Arm B receive a total of 36 fractions.
CTV will be covered by 45 Gy, GTV will be covered
by 95% of the prescribed dose, i.e. 63.1 Gy. In regard to
the organs at risk, less than 10% of the heart volume
may receive >30 Gy, less than 40% of the ipsilateral lung
may receive >20 Gy, while the mean dose in the contral-
ateral breast should be less than 5 Gy.
In case dose to the target volume and dose limits to
t h eo r g a n sa tr i s kc a nn o tb em e ta tt h es a m et i m e ,
compliance with the threshold dose in the target volume
is paramount. However, dose limitations in contralateral
structures have to be met.
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1/5 weeks with 5 fractions per
week.
Irradiation of the lymphatics
In both arms irradiation of the lymphatics will be per-
formed when indicated, according to the S3 guidelines
of the German Cancer Society [16].
Irradiation of the axillary lymph nodes is recom-
mended in following cases:
￿ Presence of residual tumor in the axilla
￿ Clinically apparent tumor spread to the axilla or in
case of positive sentinel node biopsy without or after
incomplete axillary dissection
Irradiation of the supra-/infraclavicular lymph nodes is
recommended in following cases:
￿ When more than 3 lymph node are positive
￿ In case of tumor spread to level III
Follow up
The first radio-oncologic follow-up is planned 6 weeks
after treatment completion. Further trial related follow-
up visits are scheduled at 2 years and 5 years post treat-
ment. In the time between 6 weeks and 2 years, as well
as between 2 and 5 years post treatment, follow-up
examinations are conducted by the attending gynecolo-
gists, according to the guidelines of the German Cancer
Society.
Evaluation of the cosmetic result is conducted 6 weeks
and 2 years post treatment. For complete evaluation of
overall survival, disease free survival, as well as possible
late side-effects, e.g. secondary cancer, a follow-up per-
iod of 15 years is necessary. Therefore, further trial
related documentation will be performed at 10 and 15
years post treatment.
An overview of trial related follow-up is shown in Fig-
ure 2.
Evaluation
T h ec o s m e t i cr e s u l ti se v a l u a t e dv i ap h o t o - d o c u m e n t a -
tion. Before radiotherapy, 6 weeks and 2 years post
treatment photographs of the patient’s torso are taken
in a standardized way: 2 frontal photographs from neck
to midabdomen (one with arms raised and one with
both arms alongside the body) and a profile photograph
of the treated breast (arms raised). The pictures are
evaluated by two independent investigators. Parameters
to be evaluated are skin color, teleangiectasy, scars,
shrinking and asymmetry. Evaluation is also carried
using a quantitative digitizer scoring system, as
described by Vrieling et al. [17]. Four positions are
scanned on a frontal view patient photo: the mark at
suprasternal notch, the mark at the midline 25 cm infer-
ior to the suprasternal notch, the nipple position of the
treated breast and the nipple position of the untreated
test. These are used for the calculation of a breast
retraction assessment (BRA) score. Furthermore, cos-
metic evaluation is based on the standards set forth by
the Harvard criteria [18]. An excellent score is given
when the treated breast looks essentially the same as the
contralateral, untreated breast. A good score is given for
minimal but identifiable radiation effects on the treated
breast, while a fair score is assigned for significant radia-
tion effects. A poor score is used for severe sequelae of
the treated breast.
Tumor manifestations within the residual breast, the
regional lymphatics (axillary, parasternal, infra-/supracla-
vicular) or the radiation field borders are defined as
locoregional relapse. Other types of tumor recurrence
are considered distant metastases.
Secondary cancers must be confirmed by histological
analysis. The results of the analysis should not be con-
sistent to the original histology of the primary tumor.
Date and way of diagnosis, as well as the applied dose at
t h es i t eo fo r i g i no ft h es e c o n dm a l i g n o m aa r e
documented.
Quality of life is assessed by means of the EORTC
questionnaire QLQ-C30 and the breast cancer question-
naire QLQ-BR23 at 6 weeks and 2 years post treatment.
The EORTC QLQ-C30 is an established instrument for
measuring quality of life in cancer patients and contains
30 items that measure five functional scales, global qual-
ity of life and several cancer related symptoms. The
QLQ-BR23 questionnaire is a specific tool, which con-
tains 23 items measuring functioning and symptoms
related to breast cancer [19]. Life quality assessment
should include: pain/dysaestesia (yes/no), frequence/
Figure 2 Trial follow-up.
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necessity (no/intermittent/permanent).
Statistical analysis
Primary criteria and hypotheses
Primary aim of the study is the assessment of the cos-
metic outcome and local control at 2 years after breast
radiotherapy. The question to be investigated is whether
intensity modulated radiotherapy (IMRT) is, in spite of
the reduced treatment duration, at least equivalent to
conventional therapy. The combined null hypothesis
(H0)i s“Conventional therapy is better by more than a
pre-specified margin than IMRT with respect to the cos-
metic outcome or local control”. The alternative hypoth-
esis (H1)i s :“IMRT is better, or worse at most by the
pre-specified margin than conventional radiotherapy
with respect to both cosmetic outcome and local con-
trol”. The null hypothesis will be rejected, if the lower
limits of both 95 per cent confidence intervals for the
effect of IMRT vs. standard are higher than the respec-
tive non-inferiority margin. The non-inferiority margins
are set to a relative risk of 4.67 for local control and
1.54 for the BRA measurement of cosmesis. The non-
inferiority margin for local control seems very high but
it is expected to correspond to an absolute risk differ-
ence of 7 percent (from 98 to 91 per cent). The adop-
tion of local control as a primary endpoint despite low
probability of loss of local control honours the impor-
tance of the endpoint and safeguards against too severe
concessions in this respect. As the total radiation dose is
equivalent for both arms though, it is expected that
there will be no difference in local control.
Sample size calculation
The required patient number was assessed using the
software R with a simulation of 9999 iterations. 251
patients per trial arm are required for a power of 97.5%
with reference to cosmetic result and 82.5% with refer-
ence to local control, considering a drop-out rate of
10%. The assumed drop-out rate includes patients, who
withdraw their consent to participate after randomiza-
tion, as well as patients who are not treated according
to the protocol, do not meet inclusion criteria or meet
exclusion criteria, whose data files are incomplete or
whose status is not properly assessed by follow-up
examinations.
Analysis methods
Differences in the primary endpoint “cosmetic outcome”
will be assessed by taking the variable as response in a lin-
ear model with the randomized treatment strategy, the age
of the patients and the cosmetic parameter at baseline as
explanatory variables. Local control will be estimated as
the parameter for randomized treatment in a Cox propor-
tional hazard model with age as additional explanatory
variable. Approved methods for censored data, such as
Kaplan-Meier estimation and/or log-rank test will be
applied for statistical analysis of all secondary events.
Discussion
The role of intensity modulated radiation therapy
(IMRT) in the treatment of breast cancer has been sub-
ject of investigation in various trials within recent years.
Most of the studies have performed dosimetric analyses
of IMRT compared to other radiation therapy techni-
ques. One of the first trials to directly compare IMRT
tangential photon fields versus tangential photon fields
with oblique electron-photon fields with manually opti-
mized beam wedges and wide split tangential photon
fields with computer optimized wedge angles in the
treatment of breast cancer was performed by Cho et al.
[20]. In this study, the root mean square deviation of
the differential dose-volume histogram (RMS dDVH),
which is a measure of dose homogeneity was found to
be lower for IMRT compared to the other techniques,
revealing an improved dose coverage to the treatment
volume. In the same study, the normal tissue complica-
tion probabilities (NTCPs) for the organs at risk, i.e.
heart and lungs, were calculated for comparison. The
average NTCP for excess late cardiac mortality and
radiation pneumonitis was calculated to be lower for
IMRT, while the intensity-modulated technique also
showed the lowest partial body mean dose. A further
study from the same group has shown a 50% reduction
of NTCP for late cardiac toxicity using tangential IMRT,
compared to conformal tangential fields [21].
The dosimetric advantages of inversely planned IMRT
in the treatment of breast cancer have been demon-
strated by Thilmann et al. in a plan comparison study
including 20 patients [22]. In all cases the homogeneity
in the target volume was improved for the inversely
planned IMRT compared to the 3D-planned conven-
tional radiotherapy (CRT). The volume of the ipsilateral
l u n gi r r a d i a t e dw i t had o s eh i g h e rt h a n2 0G yw a s
strongly reduced with IMRT compared to CRT (13.1%
versus 24.6% respectively). A similar trend was noticed
for the heart volume receiving a dose higher than 30 Gy
(0.2% for IMRT versus 6.2% for CRT).
More recent studies have also confirmed superior dose
distribution and homogeneity for IMRT, while also
revealing that the use of intensity modulation leads to a
reduction of the dose to the contralateral breast com-
pared to conventional tangential field techniques. Bhat-
nagar et al. showed a reduction of 36% and 57% at 4
and 8 cm respectively from the center of the medial
border of the tangential field on the contralateral breast
when IMRT was used compared to 3D-technique, a
result which was found to be highly significant [23].
Improvement of dose homogeneity with IMRT in
breast cancer has a positive influence on clinical benefits
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city. Toxicity analysis of 172 breast cancer patients trea-
ted with either IMRT or with wedge-based radiotherapy
showed a significant reduction in acute dermatitis grade
2 or worse, edema or hyperpigmentation when IMRT
was applied. Chronic edema grade 2 or worse was also
significantly reduced in favor of IMRT [24]. A signifi-
cant reduction in the occurrence of acute radiation der-
matitis using IMRT has also been demonstrated in a
multicenter double-blind, randomized clinical trial of
about 330 breast cancer patients, who were treated with
either IMRT or standard radiotherapy with wedge com-
p e n s a t i o nt oat o t a ld o s eo f5 0G yi n2 5f r a c t i o n sw i t h
an additional boost of 16 Gy when necessary [25]. This
study demonstrated a significant decrease in the occur-
rence of moist desquamation during or up to 6 weeks
post radiation treatment for the IMRT group. In parti-
cular, 31.2% of the patients treated with IMRT showed
acute radiation dermatitis, while the value was 47.8% for
the standard treatment arm. The same study showed no
correlation of IMRT with pain or quality of life, still the
presence of moist desquamation did significantly corre-
late with both pain and a reduced quality of life.
Reduced acute and late toxicity of breast IMRT results
in improved cosmetic results. A randomized trial of
standard 2D-radiotherapy versus IMRT in about 240
breast cancer patients investigated change in breast
appearance scored from serial photographs before and
after radiation treatment. This study showed that 58% of
the patients treated with 2D-radiotherapy had changes
in breast appearance, compared to 40% of the patients
treated with IMRT, while significantly fewer patients in
the IMRT group had developed palpable indurations of
the breast [26].
Several publications have confirmed the feasibility and
dosimetric superiority to conventional plans, as well as a
decrease of acute and late toxicity compared to conven-
tional radiation therapy in recent year. Despite the fact
that breast IMRT is a field of high interest, long-term,
clinical data are mostly based on retrospective analyses.
One analysis performed by McDonald et al. showed no
statistically significant differences in overall survival, dis-
ease specific survival, freedom from ipsilateral breast
tumor recurrence, distant metastasis, late toxicity or sec-
ond malignancies between 121 patients treated with IMRT
and 124 patients treated with conventional radiotherapy to
a median dose of 50 Gy, followed by a boost to a median
total dose of 60 Gy [27]. Still, the study showed a slight
trend in favor of IMRT with the 7-year freedom from ipsi-
lateral breast tumor recurrence value found to be 95% for
IMRT and 90% for conventional radiotherapy.
Therefore, the aim of our prospective, randomized,
multicentric, phase III trial is a thorough evaluation
of adjuvant IMRT for cosmesis, long-term clinical
outcomes and quality of life for breast cancer patients in
comparison to conventional 3D radiation therapy. Treat-
ment dose for both arms is calculated to be equivalent
in consideration of the linear-quadratic model. Based on
the results of previous studies we investigate the hypoth-
esis of a better cosmetic result for breast IMRT with at
least consistent radiation toxicity, local control, disease-
free survival and overall survival. Furthermore, through
boost integration in the IMRT plan, we aim to shorten
the therapy duration of about one to two weeks com-
pared to conventional treatment strategies.
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